Liuqing Yang, PhD, The University of Texas M.D. Anderson Cancer Center, will focus on the molecular mechanism of immunotherapy-associated liver impairment and its effects on a patient’s metabolic microenvironment and acquired resistance to immunotherapy treatments. Findings may influence current clinical management and pave the way for treatments targeting liver function to overcome acquired resistance.
“We are immensely thankful for the support provided by the AACR and The Mark Foundation,” said Yang. “Our studies are aimed at improving clinical outcomes for a wide range of patients undergoing immunotherapeutic cancer treatments, and the discoveries made with the support of this grant will be critical to future considerations for immunotherapy.”
Content courtesy of AACR.